Cambiar Investors LLC Reduces Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Cambiar Investors LLC cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.4% in the third quarter, Holdings Channel.com reports. The institutional investor owned 59,094 shares of the biopharmaceutical company’s stock after selling 3,376 shares during the quarter. Cambiar Investors LLC’s holdings in Regeneron Pharmaceuticals were worth $33,227,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of REGN. Dodge & Cox grew its holdings in shares of Regeneron Pharmaceuticals by 64.6% in the second quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock worth $2,008,799,000 after acquiring an additional 1,502,198 shares during the period. Norges Bank purchased a new position in Regeneron Pharmaceuticals in the second quarter worth about $628,151,000. Acadian Asset Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 234.7% during the 2nd quarter. Acadian Asset Management LLC now owns 465,740 shares of the biopharmaceutical company’s stock valued at $244,480,000 after purchasing an additional 326,583 shares during the period. Loomis Sayles & Co. L P increased its position in shares of Regeneron Pharmaceuticals by 18.6% during the 2nd quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock valued at $1,019,062,000 after purchasing an additional 305,089 shares during the last quarter. Finally, Invesco Ltd. lifted its stake in shares of Regeneron Pharmaceuticals by 26.5% in the 2nd quarter. Invesco Ltd. now owns 1,075,824 shares of the biopharmaceutical company’s stock worth $564,808,000 after purchasing an additional 225,078 shares during the period. 83.31% of the stock is owned by institutional investors.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the sale, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. This trade represents a 46.83% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the transaction, the vice president directly owned 4,233 shares in the company, valued at $2,757,503.19. This trade represents a 9.24% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $771.25 on Wednesday. The business’s 50-day simple moving average is $757.47 and its two-hundred day simple moving average is $647.23. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11. The stock has a market cap of $81.06 billion, a PE ratio of 18.47, a P/E/G ratio of 1.99 and a beta of 0.39. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. During the same quarter last year, the business posted $12.46 earnings per share. The firm’s revenue was up .9% on a year-over-year basis. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

REGN has been the subject of several recent research reports. Royal Bank Of Canada boosted their target price on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a research report on Wednesday, October 29th. Evercore ISI upped their price objective on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research note on Thursday, January 22nd. Wells Fargo & Company raised their target price on Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the stock an “equal weight” rating in a report on Wednesday, December 10th. Wall Street Zen raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Finally, Hsbc Global Res upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 24th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $784.77.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.